Article Information
History
- November 16, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Daria Bulanova1,2,*,
- Yevhen Akimov2,
- Wojciech Senkowski1,
- Jaana Oikkonen3,
- Laura Gall-Mas1,
- Sanna Timonen2,
- Manar Elmadani4,
- Johanna Hynninen5,
- Sampsa Hautaniemi3,
- Tero Aittokallio2,6,7 and
- Krister Wennerberg1
- 1Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
- 2Institute for Molecular Medicine Finland, Helsinki Institute for Life Sciences, University of Helsinki, Helsinki, Finland
- 3Research Program in Systems Oncology (ONCOSYS), University of Helsinki, Helsinki, Finland
- 4Finnish Red Cross Blood Service, Helsinki, Finland
- 5Department of Obstetrics and Gynecology, Turku University Hospital and University of Turku, Turku, Finland
- 6Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway
- 7Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Oslo, Norway
- ↵* Corresponding author; email: daria.bulanova{at}helsinki.fi
Posted November 16, 2022.
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cells
